EMEA-000084-PIP02-10
Key facts
| Invented name |
Maxalt and associated names
|
| Active substance |
Rizatriptan
|
| Therapeutic area |
Pain
|
| Decision number |
P/27/2011
|
| PIP number |
EMEA-000084-PIP02-10
|
| Pharmaceutical form(s) |
Tablet
|
| Condition(s) / indication(s) |
Treatment of migraine
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Merck Sharp & Dohme (Europe) Inc.
|
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|
| Compliance procedure number |
EMEA-C-000084-PIP02-10
|
| Compliance opinion date |
14/09/2011
|
| Compliance outcome |
positive
|